WDIV News and Press, SPDR S&P Global Dividend From 10/08/21

Global equities rose through most of the third quarter but gave up most of their gains in a volatile September. As the forces driving stock returns rapidly change in our COVID-scarred world, we believe active managers can help investors effectively navigate the recovery’s uncer...

FGD strategy and portfolio. Past performance and competitors. Takeaway. For further details see: FGD: A High Yield, Two Problems

PID strategy and portfolio. Past performance and competitors. Takeaway. For further details see: PID: Dividend Growth Mostly From Canada

VIGI strategy and portfolio. Past performance and competitors. Conclusion. For further details see: VIGI: New Index, Same Good Idea

Global Private Equity is in the lead, up 19.7% after its 2020 gain of 12.5%. Emerging Markets are the laggard with a YTD gain of just 1.5%. Commodities have come on strong this year after losing -7.8% last year. US REITs have rebounded strongly from last year's -4.7% decline. High...

SPDR S&P Global Dividend ETF (NYSEARCA:WDIV) - $0.6255. 30-Day SEC Yield of 4.33% as of Sept. 17. Payable Sep 23; for shareholders of record Sep 21; ex-div Sep 20. For further details see: SPDR S&P Global Dividend ETF declares quarterly distribution of $0.6255

The intensity of the income need only grows as investors move closer to - and enter - their retirement years. While diversified credit portfolios offer benefits, the potential drawdowns could be too much for some investors’ risk tolerances. For tax-sensitive investors, the ...

SPDR S&P Global Dividend ETF (WDIV) - $0.7740.30-Day SEC Yield of 4.14% as of Jun. 17.Payable Jun 24; for shareholders of record Jun 22; ex-div Jun 21. For further details see: SPDR S&P Global Dividend ETF declares quarterly distribution of $0.7740

WDIV invests mostly in the mid- and large-cap U.S. and non-U.S. stocks with a global dividend aristocrat status. Since rules for global dividend aristocrats are less stricter if compared to their U.S. peers, WDIV looks much less resilient than NOBL. 24% of WDIV's net assets are al...

Some in the investment community are spooked by the upcoming loss of Humira exclusivity. Revenue will likely fall in 2023, but the acquisition of Allergan, as well as the growth of revenue from Rinvoq, Skyrizi and Imbruvica should fill the gap. Management guides for high single-di...